AgingResearch.NewsJoin free

Rewind Therapeutics

CompanyBelgium

Rewind Therapeutics develops one asset, preclinical (oral GPR17 remyelination program in multiple sclerosis). Mostly small molecule acting on GPR17; based in Belgium.

1
Asset
Furthest stage
Preclinical
0
Trials
0
Signals

Pipeline

1

  • oral GPR17 remyelination program

    Antagonism of GPR17 to stimulate oligodendrocyte differentiation and remyelination in multiple sclerosis.

    Preclinical, Small molecule, GPR17, multiple sclerosis

Full company profiles: pipeline, trials, funding and people.

See Pro

In the full profile

  • Similar companies6

Intelligence